ES2377038T3 - Filtración de proteínas a contra-presión - Google Patents
Filtración de proteínas a contra-presión Download PDFInfo
- Publication number
- ES2377038T3 ES2377038T3 ES08867937T ES08867937T ES2377038T3 ES 2377038 T3 ES2377038 T3 ES 2377038T3 ES 08867937 T ES08867937 T ES 08867937T ES 08867937 T ES08867937 T ES 08867937T ES 2377038 T3 ES2377038 T3 ES 2377038T3
- Authority
- ES
- Spain
- Prior art keywords
- pressure
- protein
- filtrate
- mixture
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 102
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 102
- 238000001914 filtration Methods 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 87
- 239000007788 liquid Substances 0.000 claims abstract description 86
- 239000000706 filtrate Substances 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 54
- 239000000356 contaminant Substances 0.000 claims abstract description 24
- 239000012528 membrane Substances 0.000 claims description 36
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 31
- 102100036537 von Willebrand factor Human genes 0.000 claims description 31
- 229960001134 von willebrand factor Drugs 0.000 claims description 28
- 239000011148 porous material Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 108010054218 Factor VIII Proteins 0.000 claims description 8
- 102000001690 Factor VIII Human genes 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 230000023555 blood coagulation Effects 0.000 claims description 7
- 229960000301 factor viii Drugs 0.000 claims description 7
- 108010071289 Factor XIII Proteins 0.000 claims description 4
- 229940012444 factor xiii Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 238000005520 cutting process Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 238000011085 pressure filtration Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229920006393 polyether sulfone Polymers 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011968 cross flow microfiltration Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1741807P | 2007-12-28 | 2007-12-28 | |
| US17418P | 2007-12-28 | ||
| PCT/US2008/088005 WO2009086296A2 (en) | 2007-12-28 | 2008-12-22 | Counter-pressure filtration of proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2377038T3 true ES2377038T3 (es) | 2012-03-21 |
Family
ID=40602549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08867937T Active ES2377038T3 (es) | 2007-12-28 | 2008-12-22 | Filtración de proteínas a contra-presión |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7959809B2 (enExample) |
| EP (2) | EP2242479B1 (enExample) |
| JP (4) | JP5027310B2 (enExample) |
| KR (3) | KR101839278B1 (enExample) |
| CN (1) | CN101909599B (enExample) |
| AR (2) | AR070061A1 (enExample) |
| AT (1) | ATE525062T1 (enExample) |
| AU (1) | AU2008345218B2 (enExample) |
| CA (1) | CA2709781C (enExample) |
| DK (1) | DK2242479T3 (enExample) |
| ES (1) | ES2377038T3 (enExample) |
| HR (1) | HRP20110927T1 (enExample) |
| NZ (2) | NZ600053A (enExample) |
| PL (1) | PL2242479T3 (enExample) |
| PT (1) | PT2242479E (enExample) |
| SG (1) | SG187411A1 (enExample) |
| SI (1) | SI2242479T1 (enExample) |
| WO (1) | WO2009086296A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2377038T3 (es) * | 2007-12-28 | 2012-03-21 | Baxter International Inc. | Filtración de proteínas a contra-presión |
| TWI469992B (zh) | 2008-08-28 | 2015-01-21 | Baxter Int | 濃縮剪切靈敏生物聚合物的方法 |
| US10100594B2 (en) * | 2013-06-27 | 2018-10-16 | Ge Oil & Gas Uk Limited | Control system and a method for monitoring a filter in an underwater hydrocarbon well |
| WO2015107214A1 (en) * | 2014-01-20 | 2015-07-23 | Eveon | Process for reconstitution of a solid form of a pharmaceutical composition |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2624373C2 (de) * | 1976-05-31 | 1983-02-03 | Arnold Dr. 8782 Karlstadt Seufert | Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII |
| US5047154A (en) * | 1983-03-10 | 1991-09-10 | C.P.C. Engineering Company | Method and apparatus for enhancing the flux rate of cross-flow filtration systems |
| SE443075B (sv) * | 1984-06-01 | 1986-02-17 | Alfa Laval Agri Int | Forfarande och anordning for framstellning av mjolkkoncentrat genom membranfiltrering |
| EP0168342B1 (de) * | 1984-06-14 | 1991-07-03 | Ciba-Geigy Ag | Verfahren zur Herstellung von Thrombin-Inhibitoren |
| CA1339946C (en) * | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US4774323A (en) * | 1987-06-29 | 1988-09-27 | Rorer Pharmaceutical Corporation | Purification of von Willebrand Factor solutions using gel permeation chromatography |
| DE3730868A1 (de) | 1987-09-15 | 1989-03-23 | Henkel Kgaa | Verfahren zur abtrennung von biotechnisch hergestellten wertstoffen aus einer fermenterbruehe durch querstrom-mikro- und/oder ultrafiltration |
| SE9003452L (sv) | 1990-10-30 | 1992-05-01 | Teinvall Sjoeberg & Broberg Ab | Saett och anordning vid vaetskefiltrering |
| CH687055A5 (de) * | 1993-12-03 | 1996-09-13 | Bucher Guyer Ag Masch | Verfahren und Vorrichtung zum Eindicken von Fest/Fluessig-Gemischen mittels Membrantechnologie. |
| US5525144A (en) * | 1995-04-20 | 1996-06-11 | A/G Technology Corporation | Tangential flow filtering and separating |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| ES2149515T3 (es) * | 1996-07-10 | 2000-11-01 | American Nat Red Cross | Metodos para la separacion selectiva de componentes organicos a partir de fluidos biologicos. |
| US5888401A (en) * | 1996-09-16 | 1999-03-30 | Union Camp Corporation | Method and apparatus for reducing membrane fouling |
| AT406867B (de) * | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
| US5947689A (en) * | 1997-05-07 | 1999-09-07 | Scilog, Inc. | Automated, quantitative, system for filtration of liquids having a pump controller |
| FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| US6139878A (en) | 1998-04-27 | 2000-10-31 | Aventis Behring, Llc | Method for preparing a diafiltered stabilized blood product |
| JP4216478B2 (ja) * | 1998-09-21 | 2009-01-28 | パーダム、ハワード・イー | 感温性の材料を処理する方法および装置 |
| DE19964370B4 (de) * | 1999-02-16 | 2006-05-11 | Huss, Manfred | Herstellung eines geschäumten Molkenproteinprodukts |
| US6623781B2 (en) | 1999-07-26 | 2003-09-23 | Cornell Research Foundation, Inc. | Microfiltration of skim milk for cheese making and whey proteins |
| US6485762B1 (en) * | 1999-07-26 | 2002-11-26 | Cornell Research Foundation, Inc. | Microfiltration of skim milk for cheese making and whey proteins |
| DE10211227A1 (de) * | 2002-03-13 | 2003-10-02 | Aventis Behring Gmbh | Verfahren zur Rekonstitution von Iyophilisierten Proteinen |
| SE522048C2 (sv) | 2002-05-17 | 2004-01-07 | Hemapure Ab | Anordning och system för filtrering av blod |
| US7439013B2 (en) * | 2002-06-17 | 2008-10-21 | Asahi Kasei Kuraray Medical Co., Ltd. | Biocompatible polymer and filter for selectively eliminating leucocytes using the same |
| ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
| CA2535489C (en) * | 2003-08-14 | 2014-09-30 | D. Collen Research Foundation Vzw | Antibodies against factor viii with modified glycosylation in the variable region |
| FR2861395B1 (fr) * | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| ES2317517T5 (es) * | 2005-04-11 | 2016-01-21 | Crucell Holland B.V. | Purificación de virus usando ultrafiltración |
| ES2377038T3 (es) * | 2007-12-28 | 2012-03-21 | Baxter International Inc. | Filtración de proteínas a contra-presión |
-
2008
- 2008-12-22 ES ES08867937T patent/ES2377038T3/es active Active
- 2008-12-22 EP EP08867937A patent/EP2242479B1/en not_active Revoked
- 2008-12-22 PT PT08867937T patent/PT2242479E/pt unknown
- 2008-12-22 KR KR1020177015613A patent/KR101839278B1/ko active Active
- 2008-12-22 NZ NZ600053A patent/NZ600053A/xx not_active IP Right Cessation
- 2008-12-22 HR HR20110927T patent/HRP20110927T1/hr unknown
- 2008-12-22 JP JP2010540839A patent/JP5027310B2/ja active Active
- 2008-12-22 SI SI200830465T patent/SI2242479T1/sl unknown
- 2008-12-22 AT AT08867937T patent/ATE525062T1/de active
- 2008-12-22 AU AU2008345218A patent/AU2008345218B2/en active Active
- 2008-12-22 CA CA2709781A patent/CA2709781C/en active Active
- 2008-12-22 KR KR1020187006765A patent/KR101915445B1/ko active Active
- 2008-12-22 PL PL08867937T patent/PL2242479T3/pl unknown
- 2008-12-22 US US12/341,733 patent/US7959809B2/en active Active
- 2008-12-22 CN CN2008801239915A patent/CN101909599B/zh active Active
- 2008-12-22 KR KR1020107015781A patent/KR101748878B1/ko active Active
- 2008-12-22 NZ NZ586316A patent/NZ586316A/en not_active IP Right Cessation
- 2008-12-22 SG SG2012096392A patent/SG187411A1/en unknown
- 2008-12-22 EP EP11176408A patent/EP2392317A1/en not_active Withdrawn
- 2008-12-22 DK DK08867937.8T patent/DK2242479T3/da active
- 2008-12-22 WO PCT/US2008/088005 patent/WO2009086296A2/en not_active Ceased
- 2008-12-29 AR ARP080105761A patent/AR070061A1/es active IP Right Grant
-
2010
- 2010-08-20 US US12/860,411 patent/US8075781B2/en active Active
- 2010-08-20 US US12/860,424 patent/US8075782B2/en active Active
-
2011
- 2011-11-16 US US13/297,587 patent/US8454833B2/en active Active
-
2012
- 2012-05-07 JP JP2012105696A patent/JP5466263B2/ja active Active
-
2014
- 2014-01-23 JP JP2014009986A patent/JP5925817B2/ja active Active
-
2016
- 2016-03-03 JP JP2016040641A patent/JP2016106131A/ja active Pending
-
2019
- 2019-09-03 AR ARP190102509A patent/AR116112A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2377038T3 (es) | Filtración de proteínas a contra-presión | |
| US7919592B2 (en) | Method for separating off viruses from a protein solution by means of nanofiltration | |
| JP2011515170A (ja) | 溶媒／界面活性剤処理による生体液のウイルス不活化方法 | |
| Zadeh Mehrizi et al. | Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011–2021 | |
| Scatchard et al. | Chemical, clinical, and immunological studies on the products of human plasma fractionation. XXVI. The properties of solutions of human serum albumin of low salt content | |
| Reinhart et al. | The influence of extracorporeal circulation on erythrocytes and flow properties of blood | |
| AU2015202699B2 (en) | Counter-Pressure Filtration of Proteins | |
| BRPI0821599B1 (pt) | Métodos de filtração de uma mistura líquida de proteína | |
| CN103228285A (zh) | 用于心肺转流术的预充液 | |
| HK1150750B (en) | Counter-pressure filtration of proteins | |
| US6074560A (en) | Use of an in-line filter in the preparation of total nutrient admixtures | |
| WO2025040552A1 (en) | Method for sterile filtration of aqueous solutions containing albumin | |
| Ferenz et al. | Functionality of Albumin-derived Perfluorocarbon-Based Artificial Oxygen Carriers in the Langendorff Heart | |
| Bhatti et al. | Filters in cardiopulmonary bypass |